Clinical Trials Logo

Antiplatelet Effect clinical trials

View clinical trials related to Antiplatelet Effect.

Filter by:
  • None
  • Page 1

NCT ID: NCT04142151 Recruiting - Ischemic Stroke Clinical Trials

Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults. Half of participants will receive SanchiTongshu and one of antiplatelet drugs (Aspirin or Clopidogrel) in combination, while the other half will receive a placebo and one of antiplatelet drugs (Aspirin or Clopidogrel).

NCT ID: NCT02733640 Completed - Antiplatelet Effect Clinical Trials

Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?

Start date: October 2012
Phase: N/A
Study type: Interventional

The investigators sought to evaluate the influence of pantoprazole, indicated as less effective than other proton pump inhibitors, on the antiplatelet effect of clopidogrel, with stratification of the population according to the presence of cytochrome (CYP) 2C19 polymorphism.

NCT ID: NCT00853450 Completed - Antiplatelet Effect Clinical Trials

Bleeding Time Study With AZD6482, Clopidogrel and ASA

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.

NCT ID: NCT00688714 Completed - Antiplatelet Effect Clinical Trials

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

Start date: January 2008
Phase: Phase 1
Study type: Interventional

AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans. The primary aim for this study is to evaluate the safety and tolerability of AZD6482 in healthy human volunteers. How the substance is metabolised and eliminated from the body will also be studied. This will be done by comparing the effect of single ascending doses of AZD6482 to placebo (inactive substance).